Pfizer Inc. (NYSE:PFE) Receives Average Rating of “Hold” from Analysts

Pfizer Inc. (NYSE:PFE) has earned an average recommendation of “Hold” from the sixteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, nine have issued a hold rating, four have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $32.15.

A number of analysts have weighed in on the company. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday. Wolfe Research started coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Guggenheim cut their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was bought at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 11.11 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. Occidental Asset Management LLC grew its holdings in Pfizer by 24.8% during the second quarter. Occidental Asset Management LLC now owns 13,230 shares of the biopharmaceutical company’s stock worth $370,000 after acquiring an additional 2,627 shares during the period. Cooper Financial Group increased its holdings in shares of Pfizer by 108.2% during the 2nd quarter. Cooper Financial Group now owns 18,917 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 9,831 shares in the last quarter. Wedmont Private Capital lifted its stake in shares of Pfizer by 18.1% in the 2nd quarter. Wedmont Private Capital now owns 35,479 shares of the biopharmaceutical company’s stock valued at $1,026,000 after purchasing an additional 5,435 shares during the period. M&G Plc boosted its holdings in Pfizer by 14.5% during the second quarter. M&G Plc now owns 813,423 shares of the biopharmaceutical company’s stock worth $22,776,000 after buying an additional 103,254 shares in the last quarter. Finally, Burke & Herbert Bank & Trust Co. grew its position in Pfizer by 67.0% during the second quarter. Burke & Herbert Bank & Trust Co. now owns 76,383 shares of the biopharmaceutical company’s stock valued at $2,137,000 after buying an additional 30,647 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

PFE opened at $25.58 on Monday. The company has a market capitalization of $144.96 billion, a price-to-earnings ratio of 34.57, a PEG ratio of 0.63 and a beta of 0.65. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer has a 12-month low of $24.48 and a 12-month high of $31.54. The business’s fifty day simple moving average is $27.17 and its 200-day simple moving average is $28.27.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter last year, the firm posted ($0.17) EPS. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.72%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.